Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Dan Zeng et al
Research news Mouse experiments have suggested that glucagon-like peptide-1 receptor agonists may reduce pulmonary fibrosis following a COVID-19 infection in people with type 2 diabetes, although researchers cautioned that the findings remain preliminary Glucagon-like peptide-1 (GLP-1) receptor agonists, already used to treat type 2 diabetes (T2DM) and obesity, may also help to reduce the risk of COVID-19-related lung scarring in people with T2DM, according to research in mouse models
While some plastics used in syringes are inert, there is a risk of the peptide binding to the plastic over time, which could alter the effective dose
Available in convenient, ready-to-drink cartons
1-3 days
The compound has been shown in cell-based research to upregulate VEGFR2 transcript levels, increase phosphorylation of downstream signalling intermediates after VEGF stimulation, and enhance endothelial tube formation in matrigel assays
US$ 25.40
US$ 25.47
US$ 28.15
